# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price...
New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT® plus LAZCLUZE™ regimen...
Bill Baruch of Blue Line Capital named Dell Technologies Inc. his "final trade" on CNBC's "Halftime Report."
Johnson & Johnson boosts talc settlement offer to $9 billion, gaining support from key lawyer Allen Smith for quicker claim...
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI adva...
https://www.wsj.com/articles/johnson-johnson-wins-over-longtime-holdout-for-talc-settlement-0db573d7?page=1 Johnson & Johns...
Johnson & Johnson is ordered to pay $1 billion in damages to Auris Health shareholders for breaching a 2019 merger agreemen...